Focused On-demand Library for ADP-ribosylation factor-like protein 4A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P40617

UPID:

ARL4A_HUMAN

Alternative names:

Alternative UPACC:

P40617; A4D119; P80418; Q49AF5

Background:

ADP-ribosylation factor-like protein 4A is a pivotal small GTP-binding protein, transitioning between GDP-bound inactive and GTP-bound active forms. This cycling is finely tuned by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). Unlike other GTP-binding proteins, it does not activate the cholera toxin catalytic subunit but is essential in recruiting CYTH1, CYTH2, CYTH3, and CYTH4 to the plasma membrane in its GDP-bound state.

Therapeutic significance:

Understanding the role of ADP-ribosylation factor-like protein 4A could open doors to potential therapeutic strategies. Its intricate regulation and interaction with cellular components underscore its potential as a target in drug discovery, aiming to modulate its activity for therapeutic benefits.